Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00071747 · ClinicalTrials.gov registry record · Phase 3

Clinical Study Of Schizophrenia in Both Men and Women

A Phase 3 study of Schizophrenia, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
176
Enrollment target
20
Study locations

NCT00071747 is a Phase 3 study of Schizophrenia that has completed, run by GlaxoSmithKline. The registered enrollment target is 176 participants, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00071747, a Phase 3 study of Schizophrenia, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
176 participants
Enrollment target
20
Study locations

Study Summary

The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.

Conditions Studied

Schizophrenia

Interventions

  • DRUG lamotrigine

Study Locations (20)

California

  • GSK Investigational Site - Garden Grove
  • GSK Investigational Site - La Mesa
  • GSK Investigational Site - National City
  • GSK Investigational Site - Oceanside
  • GSK Investigational Site - Rosemead
  • GSK Investigational Site - San Diego

Florida

  • GSK Investigational Site - Maitland
  • GSK Investigational Site - North Miami

Maryland

  • GSK Investigational Site - Glen Burnie
  • GSK Investigational Site - Rockville

New Jersey

  • GSK Investigational Site - Clementon
  • GSK Investigational Site - Kenilworth

New York

  • GSK Investigational Site - Orangeburg
  • GSK Investigational Site - Rochester

Arkansas

  • GSK Investigational Site - Little Rock

Connecticut

  • GSK Investigational Site - Hartford

Illinois

  • GSK Investigational Site - Granite City

Trial Details

FieldValue
Enrollment Target 176 participants
Start Date 2003-08
Est. Completion 2005-01
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00071747

The ClinicalTrials.gov registry entry for NCT00071747 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (19% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which lamotrigine is the first listed.

NCT00071747 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT00071747 about?

NCT00071747 is a clinical study titled "Clinical Study Of Schizophrenia in Both Men and Women". The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entra...

What is the current status of trial NCT00071747?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2003-08. Estimated completion is 2005-01.

What conditions does trial NCT00071747 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT00071747?

The interventions under investigation include: lamotrigine (DRUG).

Who is sponsoring clinical trial NCT00071747?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00071747 being conducted?

This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.